Expert Interviews

Eileen Cheever, PA, discussed family hesitancy toward systemic pediatric psoriasis treatment and age-related treatment gaps in dermatology.

Aaron Farberg, MD, discusses why generalized pustular psoriasis warrants its own awareness day and how it differs immunologically from plaque psoriasis.

Victoria Garcia-Albea, NP, discussed the learning curve dermatology NP fellows experience and the need for greater dermatology education for APPs.

Oral JAK1 povorcitinib shows manageable adverse acne and strong responses even after biologic failure, offering an alternative to injections.

Jerry Shapiro, MD, explains VDPHL01's cardiac safety profile and patient-reported outcomes in a phase 2 trial for female pattern hair loss.

New IL-17 inhibitors are changing first-line choices for adolescent and adult HS alike. The panel weighs efficacy benchmarks against follow-up strategy and comorbidity screening.

Parents often hear 'biologic' and imagine the worst. The panel explains how they build trust, set expectations, and time that first injection.

Karen McGuire, PhD, CEO and co-founder of BioMendics, discusses TAMES-02 phase 2 trial enrollment and a new blister burden end point in EBS.

Lisa Swanson, MD, FAAD, discussed expanding oral JAK inhibitor options for younger children with atopic dermatitis and alopecia areata.

Martina Porter, MD, highlights phase 3 data showing povorcitinib boosts hidradenitis suppurativa responses by week 3 and sustains gains to 54 weeks in refractory patients.

With Mohs surgery complete, three stages to clear a defect greater than four centimeters extending to the periosteum, Dr. Patel details the pathology: a poorly differentiated tumor, 5.7 millimeters thick, with multifocal small-caliber perineural invasion above the clinically significant threshold.

In "Can Psoriasis Treatment Prevent PsA? Biologics, Phototherapy, and Other Treatments," Dr. Strober takes up whether some psoriasis treatments do more than clear skin.

Dr. Patel introduces the second case: a 72-year-old man with a rapidly enlarging lesion on the left forehead, now just over three centimeters, ulcerated, and sitting above the left eyebrow.

Eileen Cheever, PA, discussed how understanding immunologic pathways can strengthen patient counseling and treatment confidence in dermatology.

Leon Kircik, MD, discusses the allosteric binding mechanism and safety profile data of zasocitinib in hard-to-treat psoriasis presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

Jerry Shapiro, MD, discusses rapid hair growth and safety findings for oral minoxidil, VDPHL01, in female pattern hair loss.

Isoclear regimen combines topical isotretinoin with stage-specific ingredients from active treatment through long-term maintenance

Leon Kircik, MD, outlines phase 3 zasocitinib data on palmoplantar psoriasis skin clearance presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

Aaron Farberg, MD, discusses how localized isotretinoin delivery may affect treatment burden, tolerability, and adherence.

Kimberly Madison, DNP, and Jade Trevino, BSN, RN, discussed nurse-led triage, task shifting, and AI-supported care models for expanding dermatology access in a recent Dermatology Times interview.

Conexeu is advancing its ECM-regenerating tissue tech, targeting wound care via FDA 510(k) and eyeing aesthetics, reconstruction, and beyond.

Karen McGuire, PhD, CEO and co-founder of BioMendics, explains what fast track status means for the investigational treatment and details the drug's mechanism of action in EBS.

Examining a teenager's groin or axilla requires more than clinical skill. The panel discusses consent, comfort, and why HS diagnosis still lags for years.

A 17-year-old with painful, recurrent nodules has quietly given up gym class, social events, and her school prom. The panel walks through what her case demands.

Madison and Trevino discuss how AI can support diagnostic decisions, improve efficiency, and strengthen NP-led dermatology care

Leon Kircik, MD, discusses zasocitinib scalp psoriasis clearance rates from the LATITUDE 1 and 2 trials presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

Conexeu is developing an injectable, thermosensitive ECM scaffold to remodel skin after rapid weight loss, aiming beyond fillers to restore tissue structure.

Dr. Chandra examines the safety profiles of the checkpoint inhibitors, cautioning that patient numbers remain small and cross-trial comparisons imperfect.

The panel introduces Case 3—a patient with established CSU, co-existing dermatographia, and incomplete prior treatment records—and discusses how to confirm the diagnosis and prepare for advanced therapy.

"Modern Psoriasis Treatment: From Topicals to IL-23 and IL-17 Biologics" steps back to survey how clinicians actually treat psoriasis in 2026.